Clinical trial
Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217
NCT04534114 is registered in ClinicalTrials.gov with Bayer as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Factor XI LICA to Reduce Thrombotic Events in End-Stage Renal Disease Patients on Hemodialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of BAY 2976217
- Lead sponsor
- Bayer
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 4, 2020
- Completion date
- May 12, 2022
- Enrollment
- 307 (actual)
- Sites
- 69
Conditions
As the registry lists them; a condition with its own page is linked.
end stage renal disease requiring hemodialysis